672 results on '"Naidoo, Jarushka"'
Search Results
52. Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
53. Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
54. Contributors
55. Lung Metastases
56. Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy
57. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
58. Genome-wide cell-free DNA fragmentation in patients with cancer
59. Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
60. Immunotherapy through the Lens of Non-Small Cell Lung Cancer
61. Prospective Clinical Trials to Advance the Study of Immunotherapy Toxicities
62. Composite Pheochromocytoma with Adrenocortical Carcinoma - a rare coexistence
63. Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?
64. Supplementary Figure 1 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
65. Supplementary Tables S1 - S18 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
66. Supplementary Figures S1 - S16 from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
67. Tables S1-S7 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
68. Data from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
69. Data from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
70. Supplementary Figure Legends from Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
71. Supplementary Data 2 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
72. Supplementary Data 1 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
73. KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
74. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond
75. Supplementary Tables from Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
76. Supplementary Tables S1-S18 from Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
77. Table S3 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
78. Supplementary Table 4 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
79. Supplementary Data from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
80. Supplementary Table 5 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
81. Data from Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
82. Supplementary Table 6 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
83. Supplementary Figures 1-6 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
84. Figure S3 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
85. Supplementary Figures from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
86. Supplementary Table 1 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
87. Supplementary Figures S1-S14 from Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
88. Supplementary Table 7 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
89. Supplementary Figures from Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
90. Supplementary Table 2 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
91. Data from Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
92. PACIFIC in the Real World
93. Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity.
94. A prospective translational study investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage rectal and esophageal cancers.
95. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC
96. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
97. An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
98. Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
99. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
100. Lung Cancer in the Republic of Ireland.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.